A Pyrosequencing-based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples

Overview

Journal J Mol Diagn

Publisher Elsevier

Specialties Molecular Biology
Pathology

Date 2010 Sep 18

PMID 20847279

Citations 27

Authors

Prashanth Setty

Jennifer Hammes

Thomas Rothamel

Valentina Vladimirova

Christof M Kramm

Torsten Pietsch

Andreas Waha

Affiliations

Soon will be listed here.

Abstract

Mutations of both the IDH1 and IDH2 (isocitratedehydrogenase enzyme 1 and 2) genes have recently been described in cases of human glioma. Since IDH1 mutations have been associated with better clinical outcome, they are suitable predictive markers for adult glioma patients. We have developed a pyrosequencing assay that allows both the sensitive and rapid detection of mutant IDH1 alleles in DNA extracted from formalin-fixed, paraffin-embedded tissues. PCR products that span exon 4 of IDH1 were used as a template for pyrosequencing. For validation, PCR products were additionally cloned and sequenced conventionally by Sanger sequencing. Sensitivity was measured by titration of wild-type and mutant sequences. PCR kinetic experiments were performed to investigate the influences of PCR cycle number on the accuracy of the assay. We found that a minimum of 5% of mutant IDH1 alleles can easily be detected with the pyrosequencing approach. So far, there are few data regarding IDH1 mutation status in high-grade gliomas of childhood. Therefore, we applied this assay to 47 pediatric high-grade glioma samples (age range 6 weeks to 23 years). Mutations were found in 5/14 astrocytoma III and in 6/33 glioblastomas. In conclusion, we have developed a pyrosequencing-based assay for the detection of mutations at the hotspot regions of IDH1 and provide proof for its applicability as a molecular diagnostic assay for clinical samples.

Citing Articles

Tonabersat enhances temozolomide-mediated cytotoxicity in glioblastoma by disrupting intercellular connectivity through connexin 43 inhibition.

Schmidt E, Evert B, Pregler B, Melhem A, Hsieh M, Raspe M Mol Oncol. 2024; 19(3):878-898.

PMID: 39680504 PMC: 11887680. DOI: 10.1002/1878-0261.13786.

Two Patterns of White Matter Connection in Multiple Gliomas: Evidence from Probabilistic Fiber Tracking.

Zhang S, Su X, Kemp G, Yang X, Wan X, Tan Q J Clin Med. 2022; 11(13).

PMID: 35806978 PMC: 9267772. DOI: 10.3390/jcm11133693.

Machine learning modeling of genome-wide copy number alteration signatures reliably predicts IDH mutational status in adult diffuse glioma.

Nuechterlein N, Shapiro L, Holland E, Cimino P Acta Neuropathol Commun. 2021; 9(1):191.

PMID: 34863298 PMC: 8645099. DOI: 10.1186/s40478-021-01295-3.

Assessment of Pre-operative Measurements of Tumor Size by MRI Methods as Survival Predictors in Wild Type IDH Glioblastoma.

Palpan Flores A, Vivancos Sanchez C, Roda J, Cerdan S, Barrios A, Utrilla C Front Oncol. 2020; 10:1662.

PMID: 32984040 PMC: 7492614. DOI: 10.3389/fonc.2020.01662.

Recent Trends of microRNA Significance in Pediatric Population Glioblastoma and Current Knowledge of Micro RNA Function in Glioblastoma Multiforme.

Mazurek M, Grochowski C, Litak J, Osuchowska I, Maciejewski R, Kamieniak P Int J Mol Sci. 2020; 21(9).

PMID: 32349263 PMC: 7246719. DOI: 10.3390/ijms21093046.

References

Illingworth J, Tipton K . Purification and properties of the nicotinamide-adenine dinucleotide phosphate-dependent isocitrate dehydrogenase from pig liver cytoplasm. Biochem J. 1970; 118(2):253-8. PMC: 1179111. DOI: 10.1042/bj1180253. View

Thompson C . Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med. 2009; 360(8):813-5. PMC: 2848669. DOI: 10.1056/NEJMe0810213. View

Jennings G, Minard K, McAlister-Henn L . Expression and mutagenesis of mammalian cytosolic NADP+-specific isocitrate dehydrogenase. Biochemistry. 1997; 36(44):13743-7. DOI: 10.1021/bi970916r. View

Geisbrecht B, Gould S . The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem. 1999; 274(43):30527-33. DOI: 10.1074/jbc.274.43.30527. View

Bredel M, Pollack I, Hamilton R, James C . Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res. 1999; 5(7):1786-92. View

Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y . Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009; 100(10):1996-8. PMC: 11159618. DOI: 10.1111/j.1349-7006.2009.01270.x. View

Rickert C, Strater R, Kaatsch P, Wassmann H, Jurgens H, Dockhorn-Dworniczak B . Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol. 2001; 158(4):1525-32. PMC: 1891902. DOI: 10.1016/S0002-9440(10)64103-X. View

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F . Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27(25):4150-4. DOI: 10.1200/JCO.2009.21.9832. View

Pollack I, Hamilton R, Finkelstein S, Campbell J, Martinez A, Sherwin R . The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 1997; 57(2):304-9. View

10.

Waha A, Felsberg J, Hartmann W, von dem Knesebeck A, Mikeska T, Joos S . Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res. 2010; 70(4):1689-99. DOI: 10.1158/0008-5472.CAN-09-3218. View

11.

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

12.

Kato Y, Jin G, Kuan C, McLendon R, Yan H, Bigner D . A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun. 2009; 390(3):547-51. PMC: 2788025. DOI: 10.1016/j.bbrc.2009.10.001. View

13.

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A . Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116(6):597-602. DOI: 10.1007/s00401-008-0455-2. View

14.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

15.

Cogswell P, Morgan R, Dunn M, Neubauer A, Nelson P, Sandberg A . Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood. 1989; 74(8):2629-33. View

16.

Pietsch T, Taylor M, Rutka J . Molecular pathogenesis of childhood brain tumors. J Neurooncol. 2005; 70(2):203-15. DOI: 10.1007/s11060-004-2750-7. View

17.

Kleihues P, Louis D, Scheithauer B, Rorke L, Reifenberger G, Burger P . The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61(3):215-25; discussion 226-9. DOI: 10.1093/jnen/61.3.215. View

18.

Fakhrai-Rad H, Pourmand N, Ronaghi M . Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat. 2002; 19(5):479-85. DOI: 10.1002/humu.10078. View

19.

Raffel C, Frederick L, OFallon J, Perry A, Jenkins R, James C . Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res. 2000; 5(12):4085-90. View

20.

Watanabe T, Nobusawa S, Kleihues P, Ohgaki H . IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009; 174(4):1149-53. PMC: 2671348. DOI: 10.2353/ajpath.2009.080958. View